WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Who is this study for? Adult patients with prostate cancer
What treatments are being studied? Walnuts
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP. Patients consented to the study will be randomly assigned to either continue their usual diets (control arm) or to the walnut arm for 4-10 weeks depending on the window between their consent date and the date for RP.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:

• Pathologically confirmed prostate adenocarcinoma.

• Diagnostic biopsy cores with ≥10 cores with each core examined separately to determine exact tumor location.

• Biopsy grade group 2 or higher (Gleason ≥7).

• Planning to undergo RP.

• Willing to adhere to a usual diet with the possible addition of 2 oz of walnuts per day.

• Reads, writes, and understands English.

• Age 18 or older

Locations
United States
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
North Carolina
Durham VA Medical Center
RECRUITING
Durham
Contact Information
Primary
Yunhee Choi-Kuaea, MSW
Yunhee.Choi-Kuaea@cshs.org
310-423-0333
Time Frame
Start Date: 2019-04-22
Estimated Completion Date: 2026-12
Participants
Target number of participants: 50
Treatments
Experimental: Usual Diet + Walnuts
Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
Active_comparator: Usual Diet
Usual diet for 4-10 weeks
Related Therapeutic Areas
Prostate Cancer
Sponsors
Collaborators: California Walnut Commission
Leads: Stephen Freedland

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%: an Open-label, Single-center, Non-inferiority Randomized Controlled Study

Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%: an Open-label, Single-center, Non-inferiority Randomized Controlled Study

Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Procedure
Study Phase: Not Applicable

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)

Enrollment Status: Recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Phase: Phase 2

Extracorporeal Shockwave Therapy for Penile Rehabilitation in Post-Radical Prostatectomy Patients: A Randomized, Double-Blinded, Sham-Controlled Study

Extracorporeal Shockwave Therapy for Penile Rehabilitation in Post-Radical Prostatectomy Patients: A Randomized, Double-Blinded, Sham-Controlled Study

Enrollment Status: Recruiting
Publish Date: October 11, 2023
Intervention Type: Device
Study Phase: Not Applicable
View All